 NEW HAVEN, Conn., April 07, 2021 GLOBE NEWSWIRE -- Trevi Therapeutics, Inc. Nasdaq: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host investor meetings, at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021. Trevis presentation is scheduled for 2:15 p.m. ET. 